Table 3.
CXCL1 protein levels in HNSCC patients’ serum (n = 40)
| Characteristic | Serum, median (range) | p-value |
|---|---|---|
| Age at the time of surgery (years) | ||
| ≤ 60 | 4.935 (1.558–11.43) | 0.6151a |
| > 60 | 2.792 (0.2597–11.95) | |
| Gender | ||
| Male | 2.792 (0.2597–11.95) | 0.2916a |
| Female | 5.974 (2.338–8.052) | |
| Tumor stage (TNM classification) | ||
| T1 | 3.247 (1.558–4.935) | 0.5116b |
| T2 | 2.987 (2.597–5.714) | |
| T3 | 2.208 (0.2597–11.95) | |
| T4 | 3.571 (1.429–11.43) | |
| N0 | 2.532 (1.169–11.95) | 0.1093b |
| N1 | 4.286 (0.2597–11.30) | |
| N2 | 5.390 (2.597–11.43) | |
| N3 | 1.688 (1.429–1.948) | |
| Histologic grade | ||
| G1 | 2.208 (1.169–4.935) | 0.0119b |
| G2-G3 | 5.195 (2.597–7.013) | |
| Anatomical site | ||
| Larynx | 4.351 (1.818–11.95) | 0.1564a |
| Oral cavity | 2.792 (0.2597–11.43) | |
The serum CXCL1 protein levels were measured in duplicates using ELISA. Depending on the data distribution we performed the U Mann–Whitney testa or Kruskal–Wallis testb